Heparin, Low-Molecular-Weight

• 

  Subject Areas on Research

  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. 
  • A perioperative strategy for the placement of a thoracic epidural catheter in a pediatric patient on high-dose enoxaprin. 
  • A rare cutaneous manifestation of hemorrhagic bullae to low-molecular-weight heparin and fondaparinux: report of two cases. 
  • A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation. 
  • Advances in the approach to acute coronary syndromes. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. 
  • Anticoagulant therapy during cardiopulmonary bypass. 
  • Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 
  • Anticoagulant therapy in unstable angina. 
  • Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study. 
  • Anticoagulation in acute cardiac care in patients with chronic kidney disease. 
  • Anticoagulation therapy. 
  • Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. 
  • Bridging Anticoagulation in Patients with Atrial Fibrillation. 
  • Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. 
  • Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. 
  • Coagulation abnormalities and thrombosis in patients with COVID-19. 
  • Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. 
  • Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. 
  • Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. 
  • Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. 
  • Economics of low-molecular weight heparins. 
  • Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. 
  • Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. 
  • Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. 
  • Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). 
  • Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. 
  • Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. 
  • Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. 
  • Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. 
  • Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. 
  • From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). 
  • Future alternatives to heparin: low-molecular-weight heparin and hirudin. 
  • Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. 
  • Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. 
  • Heparins: their established role in acute coronary syndromes and perspectives in atrial fibrillation. 
  • Hospital variability in use of anticoagulant strategies during acute myocardial infarction treated with an early invasive strategy. 
  • Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. 
  • Improved microsurgical anastomotic patency with low molecular weight heparin. 
  • Influence of clinical trial participation on subsequent antithrombin use. 
  • Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. 
  • Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). 
  • Issues in the utilization of low molecular weight heparins. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot study to assess the feasibility of a randomized, open-label trial. 
  • Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. 
  • Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. 
  • Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease. 
  • Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes. 
  • Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. 
  • Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. 
  • Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. 
  • Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. 
  • PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses. 
  • Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. 
  • Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. 
  • Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 
  • Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. 
  • Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims. 
  • Poor Adherence to Risk Stratification Guidelines Results in Overuse of Venous Thromboembolism Prophylaxis in Hospitalized Older Adults. 
  • Portal vein thrombosis: an unexpected finding in a 28-year-old male with abdominal pain. 
  • Post-operative pharmacologic thromboprophylaxis after major hepatectomy: does peripheral venous thromboembolism prevention outweigh bleeding risks? 
  • Potassium homeostasis in patients receiving prophylactic dose enoxaparin therapy. 
  • Practice bulletin no. 123: thromboembolism in pregnancy. 
  • Preclinical differentiation of low molecular weight heparins. 
  • Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. 
  • Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. 
  • Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery. 
  • Prevention and management of venous thromboembolism in pregnancy. 
  • Prevention and treatment of venous thromboembolism in pregnancy. 
  • Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. 
  • Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). 
  • Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. 
  • Pursuing progress in acute coronary syndromes. 
  • Recombinant Human Antithrombin in Pregnant Patients with Hereditary Antithrombin Deficiency: Integrated Analysis of Clinical Data. 
  • Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. 
  • Redefining medical treatment in the management of unstable angina. 
  • Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. 
  • Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. 
  • Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. 
  • Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE. 
  • Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. 
  • Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion. 
  • Simple principles of clinical trials remain powerful. 
  • The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. 
  • The management of Cesarean delivery in a parturient with paroxysmal nocturnal hemoglobinuria complicated by severe preeclampsia. 
  • The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. 
  • Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. 
  • Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. 
  • Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. 
  • To bridge or not to bridge: these are the questions. 
  • Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. 
  • Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. 
  • Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). 
  • Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. 
  • Venous thromboembolism debate in joint arthroplasty. 
  • Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. 
  • When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Arepally, Gowthami Morey, Professor of Medicine, Pathology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology